Drug Profile
Anthrax immune globulin - Emergent BioSolutions
Alternative Names: AIG; Anthrax IG Therapeutic - Emergent BioSolutions; Anthrax Immune Globulin Intravenous (AIGIV) - Emergent BioSolutions; AnthrivigLatest Information Update: 08 Feb 2022
Price :
$50
*
At a glance
- Originator Emergent BioSolutions
- Class Antibacterials; Immunoglobulins; Polyclonal antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Anthrax
Most Recent Events
- 03 Sep 2019 Discontinued - Phase-III for Anthrax (In volunteers) in USA (IV)
- 18 Sep 2015 No recent reports on development identified - Phase-III for Anthrax (In volunteers) in USA (IV)
- 08 Mar 2013 Anthrax immune globulin - Emergent BioSolutions receives Orphan Drug status for Anthrax in European Union